Rift valley fever: Next generation vaccines for an old foe by Bird, Brian
Engineering Conferences International
ECI Digital Archives
Vaccine Technology IV Proceedings
Spring 5-22-2012
Rift valley fever: Next generation vaccines for an
old foe
Brian Bird
Viral Special Pathogens Branch Centers for Disease Control and Prevention
Follow this and additional works at: http://dc.engconfintl.org/vaccine_iv
Part of the Biomedical Engineering and Bioengineering Commons
This Conference Proceeding is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in
Vaccine Technology IV by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.
Recommended Citation
Brian Bird, "Rift valley fever: Next generation vaccines for an old foe" in "Vaccine Technology IV", B. Buckland, University College
London, UK; J. Aunins, Janis Biologics, LLC; P. Alves , ITQB/IBET; K. Jansen, Wyeth Vaccine Research Eds, ECI Symposium Series,
(2013). http://dc.engconfintl.org/vaccine_iv/23
CDC Rift Valley fever Vaccine Initiative
Brian Bird DVM, MSPH, PhD
Viral Special Pathogens Branch
Centers for Disease Control and Prevention
Viral Special Pathogens Branch
• Focus on viral hemorrhagic fevers 
(>35 viruses, 5 Families)
– BSL-4, BSL-3+, BSL-2 labs
• Diagnostics – Outbreak Response




– molecular biology, pathogenesis, 
immunology, vaccines and anti-viral 
therapeutic drugs
• Ecology
– Uganda (Ebola, Marburg)
– South America (hantaviruses)
– Eastern and Southern Africa (RVF)
Rift Valley fever virus
• Mosquito-borne RNA virus (Bunyaviridae)
• (Aedes sp. mosquitoes most important)
• Endemic throughout Africa and parts of Arabian 
Peninsula
• Outbreaks linked to extensive rainfall – mosquito 
abundance
• Outbreaks are extensive
• humans (10s to 100s thousands)
• livestock (millions)
• Threat of introduction into Middle East, Europe or US
• Many competent mosquito vectors in North America
• Potential bioterrorism threat
RVF disease
• Humans
• Majority: self limiting
febrile illness
~1-2% of cases
ACUTE: hepatitis  > 
hemorrhagic syndrome 
• (10-20% case fatality)
DELAYED: encephalitis, retinitis, 
blindness
• Direct contact with infected 
livestock is the key risk factor 
for severe and lethal disease 
RVF disease
• Livestock
• Sheep, cattle, goats 
• Camelids
• Abortion storms 
• near 100% sheep and cattle
• High newborn mortality 
• 80-100%
• Adult mortality 
• 5-20%
• Wildlife: Cape Buffalo transient viremia, 
many other species IgG positive
• Horses, swine, poultry unaffected
Current status of RVF vaccines
• No commercially available human or livestock 
vaccines for use in the U.S. and Europe
• Exciting time in RVFV vaccine research 
– Recombinant MLAV, VLP, VRP, Paramyxo vectored, Pox 
virus vectored etc.
• A couple of livestock vaccines in limited use in Africa 
(OBP, South Africa):
– inactivated vaccine 
– live attenuated vaccines: Smithburn strain 
• abortions, teratology, other fetal abnormalities
• No capacity to differentiate vaccinated from 
naturally infected animals
• Clone 13 LAV may be an improvement with fewer 
adverse effects
CDC RVF vaccine development strategy
• Virus amplification in livestock leads to explosive outbreaks and is 
needed to get spillover into humans
• Disease in livestock precedes disease in humans by ~ 1 month
• Significantly easier to get vaccines approved for livestock than  
humans
• One Health – good livestock vaccines should indirectly reduce or 
prevent human disease
• Vaccine design should allow for further development in humans
– (FDA animal rule)
…or why is CDC working on a livestock vaccine ???
Don’t you work on people diseases???
One Health – good livestock 
vaccines should indirectly 
reduce or prevent human 
disease
Bird and Nichol
Curr Opinion in Virol,2012
Ideal RVF vaccine properties
• Precise identity and excellent purity
• Safety – No post-vax disease; no abortions or fetal 
abnormalities (Historically this has been a BIG problem)
• Single dose, rapid and long lasting protection
- best achieved with live attenuated vaccine
• Multiple attenuating lesions/ absence of reversion
• Inexpensive (produced at high titers = cheap/dose)
• Differentiate infected from vaccinated animals
- DIVA
Towards rational vaccine design
• Reverse genetics approach
– Generation of precisely engineered infectious virus 
from plasmid DNA
– Identify and knock out critical virus virulence genes




















Deletion of 70% NSs 
ORF attenuated in 
mice
LD50  ~4 logs
Muller et. al. 1995
rats
LD50 ~3 logs
Bird et. al., 2007
NSm
NSs

















• Excellent safety with either candidate 
when given at doses up to 10,000x LD50 of 
virulent virus (LD50 = < 1.0 PFU)
• Complete protection from up to 10,000x 
LD dose of virulent virus 28 days post-vax50
Robust IgG response >1:6400
• PRNT80 >1:1256
• Rapid protection up to 100% within 
48 hours post-vaccination in mice
Rodent results
• Excellent safety with either candidate 
when given at doses up to 10,000x LD50 of 
virulent virus
• Complete protection from up to 10,000x 
LD dose of virulent virus 28 days post-vax50
Robust IgG response >1:6400
• PRNT80 >1:1256
BUT WHAT ABOUT A 
RELEVANT HOST?????
∆/∆ Vaccine Sheep Trial
Bird et al., Journal of Virology 2011
Deltamune Pty. Ltd. South Africa
• Safety and Efficacy Trial
• timed pregnant ewes
• 1.0x104 PFU SC
• N=29 vaccinates, N=3 sham controls
• Vacc. at day 42 gestation: 
• (fetus most sensitive to teratogenesis, MP12/Smithburn)
∆/∆ Vaccine Trial Timeline
Dr. Barbara Knust
Day of Pregnancy





Safety 1 : Vax early gestation:  
N=29 + 3 shams
∆/∆ Vaccine Trial Timeline
Day of Pregnancy





Safety 1 : Vax early gestation:  
N=29 + 3 shams
∆/∆ Vaccine Trial Timeline
Day of Pregnancy




U/S U/S Preg Dx
Safety 2: NO CHALLENGE, 
Monitor through full-term N=20
Safety 1 : Vax early gestation:  
N=29 + 3 shams
∆/∆ Vaccine Trial Timeline
Day of Pregnancy






U/S U/S Preg Dx
Safety 2: NO CHALLENGE, 
Monitor through full-term N=20
Safety 1 : Vax early gestation:  
N=30 + 3 shams
∆/∆ Vaccine Trial Timeline
Day of Pregnancy
0 42 90 121 142/D+1
Vax Efficacy/Challenge  









U/S U/S Preg Dx
∆/∆ Safety and Immunogenicity 
post-Vaccination
Shelley Campbell
All vaccinated animals (N=29) seroconverted
No fever detected post-vaccination
No other adverse events detected
No seroconversion in contact controls (N=3)
∆/∆ EFFICACY
• Challenge (n=9) at Day 121 pregnancy or 82 days post-vax
• No abortion or viremia in vaccinated animals
– Vacc. ewes: NO viremia or fever; day 1 to 14 
– Lambs born to vacc ewes: virus neg. (blood, liver, brain)
• All shams (n=3) aborted by day 6 PC
∆/∆ EFFICACY
• Challenge (n=9) at Day 121 pregnancy or 82 days post-vax
• No abortion in vaccinated animals
– Vacc. ewes: NO viremia or fever; day 1 to 14 
– Lambs born to vacc ewes: virus neg. (blood, liver, brain)
• All shams (n=3) aborted by day 6 PC
Differentiating Infected from Vaccinated Animals
Built into vaccine design
















Ideal RVF vaccine properties
Precise identity and excellent purity
– generated from plasmid DNA of 100% exact sequence
Safety - ∆/∆ NOT a Select Agent, RSA and CDC IBC = BSL-2, awaiting 
more broad NIH RAC classification
– NO adverse events in rodents (n~350)
– NO adverse event in adult  or pregnant sheep (n=42 total)
Single dose rapid protection
Mice 100% protection by 48-72 hrs–
Multiple attenuating lesions/ avoid reversion
– 2 complete virus gene deletions
Differentiate infected from vaccinated animals
– DIVA based on vaccine lacking NSs and NSm genes
Excellent “Environmental containment”
– Does not infect mosquito vectors (Crabtree et al, PLoS NTD 2012); no viremia in vaccinates
Inexpensive





Stuart Nichol Baltus Erasmus
Kimberly Dodd
Lake Naivasha, Kenya
Site of first reported RVF outbreak 1930
